XML 59 R8.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Class A Common Stock
Common Stock
Class A Common Stock
Treasury Stock
Additional Paid-In Capital
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss)
Non-Controlling Interest
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
End of period (in shares)         (22,614,052)          
Beginning of period (in shares) at Mar. 31, 2020       161,333,973            
Beginning of period at Mar. 31, 2020 $ 856,356 $ (1,180)   $ 1,613 $ (898,095) $ 468,027 $ 1,330,812 $ (1,180) $ (46,001) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of common stock (in shares)       1,112,183            
Issuance of common stock 18,814     $ 11   18,803        
Stock options exercised (in shares)       504,450            
Stock options exercised 11,747     $ 5   11,742        
Repurchase of common stock (in shares)         (4,090,525)          
Repurchase of common stock (318,068)       $ (318,068)          
Recognition of liability related to future restricted stock units vesting (456)         (456)        
Net income 608,958           608,958      
Other comprehensive income, net of tax 16,230               16,230  
Dividends paid (181,066)           (181,066)      
Stock-based compensation expense 59,841         59,841        
End of period (in shares) at Mar. 31, 2021       162,950,606            
End of period at Mar. 31, 2021 1,071,176     $ 1,629 $ (1,216,163) 557,957 1,757,524   (29,771) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
End of period (in shares)         (26,704,577)          
Issuance of common stock (in shares)       1,224,207            
Issuance of common stock 22,170     $ 15   22,155        
Stock options exercised (in shares)       197,732            
Stock options exercised 5,929     $ 2   5,927        
Repurchase of common stock (in shares)     (4,700,000)   (5,083,620)          
Repurchase of common stock (419,291)       $ (419,291)          
Recognition of liability related to future restricted stock units vesting 1,213         1,213        
Net income 466,577           466,740     (163)
Other comprehensive income, net of tax 38,356               38,356  
Dividends paid (209,193)           (209,193)      
Stock-based compensation expense 69,784         69,784        
Contribution to non-controlling interest $ 0         (814)       814
End of period (in shares) at Mar. 31, 2022 132,584,348     164,372,545            
End of period at Mar. 31, 2022 $ 1,046,721     $ 1,646 $ (1,635,454) 656,222 2,015,071   8,585 651
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
End of period (in shares) 31,788,197       (31,788,197)          
Issuance of common stock (in shares)       1,170,726            
Issuance of common stock $ 24,663     $ 10   24,653        
Stock options exercised (in shares)       329,061            
Stock options exercised 11,384     $ 3   11,381        
Repurchase of common stock (in shares)     (2,100,000)   (2,446,547)          
Repurchase of common stock (224,451)       $ (224,451)          
Net income 271,215           271,791     (576)
Other comprehensive income, net of tax 20,748               20,748  
Dividends paid (235,407)           (235,407)      
Stock-based compensation expense 80,272         80,272        
Contribution to non-controlling interest 0         (3,068)       3,068
De-Consolidation of non-controlling interest $ (3,143)                 (3,143)
End of period (in shares) at Mar. 31, 2023 131,637,588     165,872,332            
End of period at Mar. 31, 2023 $ 992,002     $ 1,659 $ (1,859,905) $ 769,460 $ 2,051,455   $ 29,333 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
End of period (in shares) 34,234,744       (34,234,744)